Your browser doesn't support javascript.
loading
Alpha-Emitting Radionuclides: Current Status and Future Perspectives.
Miederer, Matthias; Benesová-Schäfer, Martina; Mamat, Constantin; Kästner, David; Pretze, Marc; Michler, Enrico; Brogsitter, Claudia; Kotzerke, Jörg; Kopka, Klaus; Scheinberg, David A; McDevitt, Michael R.
Afiliação
  • Miederer M; Department of Translational Imaging in Oncology, National Center for Tumor Diseases (NCT/UCC), 01307 Dresden, Germany.
  • Benesová-Schäfer M; Medizinische Fakultät and University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.
  • Mamat C; German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
  • Kästner D; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 01328 Dresden, Germany.
  • Pretze M; Research Group Molecular Biology of Systemic Radiotherapy, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
  • Michler E; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstr, 400, 01328 Dresden, Germany.
  • Brogsitter C; School of Science, Faculty of Chemistry and Food Chemistry, Technische Universität Dresden, 01062 Dresden, Germany.
  • Kotzerke J; Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, 01307 Dresden, Germany.
  • Kopka K; Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, 01307 Dresden, Germany.
  • Scheinberg DA; Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, 01307 Dresden, Germany.
  • McDevitt MR; Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, 01307 Dresden, Germany.
Pharmaceuticals (Basel) ; 17(1)2024 Jan 08.
Article em En | MEDLINE | ID: mdl-38256909
ABSTRACT
The use of radionuclides for targeted endoradiotherapy is a rapidly growing field in oncology. In particular, the focus on the biological effects of different radiation qualities is an important factor in understanding and implementing new therapies. Together with the combined approach of imaging and therapy, therapeutic nuclear medicine has recently made great progress. A particular area of research is the use of alpha-emitting radionuclides, which have unique physical properties associated with outstanding advantages, e.g., for single tumor cell targeting. Here, recent results and open questions regarding the production of alpha-emitting isotopes as well as their chemical combination with carrier molecules and clinical experience from compassionate use reports and clinical trials are discussed.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Pharmaceuticals (Basel) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Pharmaceuticals (Basel) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha